Form 4: Neuphoria Therapeutics Director Alan Fisher Acquires Restricted Stock Units

Director Alan Fisher reports acquisition of restricted stock units in Neuphoria Therapeutics.

Summary

• On April 16, 2025, Alan Fisher, a director of Neuphoria Therapeutics Inc. (NEUP), acquired 13,566 Restricted Stock Units (RSUs).
• These RSUs represent a contingent right to receive one share of common stock each.
• The RSUs will fully vest on the day prior to the company's next annual shareholder meeting, expected no later than November 30, 2025, contingent upon continuous service to the company.
• Following this transaction, Fisher directly owns 13,658 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects an insider's increased stake in the company, suggesting confidence. However, it's a routine transaction.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the RSUs is contingent upon the reporting person's continuous service to the company through the day prior to the company's next annual shareholder meeting, which is expected to be no later than November 30, 2025.

Industry Context

This is a standard disclosure related to insider transactions, common in publicly traded companies to ensure transparency.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholders as it signals confidence from a company director.

Next Steps

• The RSUs will vest subject to continued service through the day prior to the company's next annual shareholder meeting.

Key Dates

Keywords

Restricted Stock Units, Director, Form 4, NEUP, Neuphoria Therapeutics, Beneficial Ownership, Alan Fisher